Zavation’s eZspand Lateral Lumbar Interbody Fusion Device Receives the US FDA’s Clearance for the Treatment of Degenerative Disc Disease
Shots:
- The company has received the US FDA 510(k) clearance for its eZspand Lateral expandable lumbar interbody fusion device
- The device offers continual expansion to optimize the fit for each patient along with improved structural stability and sagittal balance. Additionally, patients who have completed 6mos. of non-operative treatment should utilize the device
- In skeletally mature patients, Zavation eZspand interbody system implants are recommended for use with autogenous bone transplant in spinal fusion procedures & are designed to treat DDD with up to grade I spondylolisthesis at one or two contiguous levels in the lumbar spine from L2 to S1
Ref: PRNewswire | Image: Zavation
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
